Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Shenmai Shuxin
- Development stage
- Unknown
- Lead developer
- Nanjing Chia-Tai Tianqing Pharmaceutical
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
Shenmai Shuxin is a Traditional Chinese Medicine (TCM) formulation developed by Nanjing Chia Tai Tianqing Pharmaceutical, specifically in the form of dripping pills. It is derived from the classic Shenmai formula, which typically consists of *Panax ginseng* and *Ophiopogon japonicus*. The drug is primarily indicated for the treatment of coronary heart disease and angina pectoris, particularly in patients diagnosed with the Qi and Yin deficiency syndrome according to TCM principles. It is designed to improve myocardial blood supply, protect heart tissue, and alleviate symptoms such as chest pain and palpitations. Clinical evaluation has focused on its efficacy and safety in managing stable angina pectoris.
- Brand names
- Shenmai Shuxin
- Other names
- Shenmai Shuxin Dripping Pills参麦舒心滴丸
02
Targets
OATP1B1 (Organic anion transporting polypeptide 1B1)SLCO1B3 (Organic anion transporting polypeptide 1B3)
Beyond the preview
Go deeper on Shenmai Shuxin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Shenmai Shuxin.